Navigation Links
Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
Date:1/8/2008

cancer and study participants will be randomized in one of two arms of the trial (1:1), to receive either NKTR-102 and cetuximab or standard irinotecan and cetuximab. The Phase 2b stage is expected to begin in mid-year 2008 and will be conducted in over 40 centers worldwide. The primary endpoint of the Phase 2b trial is progression-free survival. Secondary endpoints include response rate, response duration, overall survival, standard pharmacokinetics, and incidence of toxicities, including diarrhea and neutropenia.

Prior Data Presentations for NKTR-102

Peer-reviewed presentations of preclinical study results for NKTR-102 were presented at ECCO 14 and the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in the fall of 2007. These presentations can be found at: http://www.nektar.com/wt/page/nktr102media

About NKTR-102

Nektar is developing NKTR-102, a PEGylated form of irinotecan, which was invented by Nektar using its world-leading small molecule PEGylation technology platform. The product is currently in Phase 2 clinical development. Irinotecan, also known as Camptosar, is an important chemotherapeutic agent used for the treatment of solid tumors, including colorectal and lung cancers. By applying Nektar's small molecule PEGylation technology to irinotecan, NKTR-102 may prove to be a more powerful and tolerable anti-tumor agent.

Preclinical studies show that treatment with NKTR-102 results in significant suppression of tumor growth in an irinotecan-resistant mouse colorectal tumor model. Administration of NKTR-102 in an animal model results in a significantly improved time-concentration profile for the active metabolite of irinotecan as compared to treatment with standard irinotecan.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its indu
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
2. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
3. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
4. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
5. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
6. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
7. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... The Detroit Medical Center (DMC) Cardiovascular Institute (CVI) ... to successfully open a patient,s blocked artery with a ... drill" to painlessly remove the plaque buildup which causes ... – conducted Wednesday by CVI Director of Endovascular Medicine ...
... HistoRx, the leader in quantitative immunohistochemistry, advances ... recent issuance of US patents covering key features ... results.  The U.S. Patent and Trademark Office has ... for standardization of digital microscopy instruments, methods required ...
Cached Medicine Technology:DMC Cardiovascular Institute Physician is First in Michigan to Use New "Arterial Drill" Catheterization Technique to Remove a Major Blockage 2DMC Cardiovascular Institute Physician is First in Michigan to Use New "Arterial Drill" Catheterization Technique to Remove a Major Blockage 3HistoRx Earns Two Additional Patents on Standardization of Results from Digital Pathology Instruments 2HistoRx Earns Two Additional Patents on Standardization of Results from Digital Pathology Instruments 3
(Date:7/13/2014)... MillionaireCasket.com is a professional supplier of funeral products. According to ... well in the global market. Recently, the company has announced ... a special offer for all the newly released items. ... caskets are made with superb materials. As is commonly noted, ... respect to the departed saint. MillionaireCasket.com is always here to ...
(Date:7/13/2014)... 13, 2014 Intraocular Lens (IOL) Market: ... 2013 - 2019 , Intraocular lens (IOL) is inserted ... or cataracts. The lenses are inserted inside the eye, ... intraocular lens replaces the focusing power of natural lens. ... lens to deliver the light focusing function which was ...
(Date:7/13/2014)... Victorian Hotel has recently announced that ... of bikes for its "Cycle the City" program, which ... tour the area using a rental bicycle, available for ... to call Vancouver home, as it is a city ... picturesque journeys through the countryside. Vancouver hotel rooms often ...
(Date:7/13/2014)... additives are chemicals, which are added to various fuels ... on, in order to enhance their performance. Fuel additives ... by fuels and improving the combustion properties of fuels. ... scale in the long run, but, in the short ... products. , The various fuel additive types include deposit ...
(Date:7/13/2014)... The Pearland, Texas location of The Little Gym, a ... to 12 years of age that offers everything from gymnastics, ... Summer Camps, is now under new ownership. , Kevin Berry ... spending over six years at The Little Gym of Bellaire ... Berry has over ten years of experience working with children, ...
Breaking Medicine News(10 mins):Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2
... ... received its first batch of Spirits Bay Manuka Honey tested for activity using ... is a registered trademark of the University of Waikato, home of the Honey ... of manuka honey. Produced by a Maori-owned apiary in a remote area of ...
... ... employee wellness programs , ... GA (Vocus) April 7, 2010 -- R. Shane Jackson, president of LocumTenens.com and ... for Health Transformation,s (CHT) first member meeting of 2010, which took place on March 25 ...
... poor people have higher death rates than rich within first decade ... more likely to die within five to 10 years after heart ... 15,156 white men, 6,932 white women, 678 black men and 564 ... and 2005 and found that the poorest patients were 19 to ...
... , ... today released version 4.3 of Replay, the award-winning, next generation backup and disaster recovery ... ... 4.3 of Replay, the award-winning, next generation backup and disaster recovery software solution. ...
... a means of heterosexual interaction on university campuses, more women ... women rate hooking up above dating. Both genders however perceive ... Bradshaw from James Madison University in Virginia, US, and colleagues ... hook up or to date, as well as the perceived ...
... vaccine were at higher risk, study found, but that ... (HealthDay News) The traditional seasonal flu vaccine may ... swine flu, according to the results of four new ... researchers used an ongoing sentinel monitoring system to assess ...
Cached Medicine News:Health News:Koru Naturals Becomes the First U.S. Company to Import Molan Gold Standard Manuka Honey 2Health News:R. Shane Jackson Selected as Panelist for Center for Health Transformation Member Meeting 2Health News:R. Shane Jackson Selected as Panelist for Center for Health Transformation Member Meeting 3Health News:Poor More Likely to Die Following Heart Surgery 2Health News:De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V 2Health News:De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V 3Health News:Hooking up or dating: Who benefits? 2Health News:Did 'Regular' Flu Shot Up Risks for H1N1 Flu? 2
The Freedom Clear® LS Long Seal is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for everyday wear. Its long seal provides added security....
Freedom Clear® SS Sport Sheath is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath designed for everyday wear. Its brief sheath minimizes roll at the base of the p...
The UltraFlex® all silicone self-adhering male external catheter is 100% latex-free and eliminates the risk of latex-related skin irritations. This breathable catheter promotes healthy skin and i...
... all-silicone Foley catheters eliminate patient exposure ... catheter designs. As an inert, toxin-free ... a safe, dependable Foley catheter. Unlike ... catheters will not leach chemicals or ...
Medicine Products: